|

Cretostimogene Grenadenorepvec Clinical Trials

2 actively recruiting trials across 1 location

Also known as: CG0070

Pipeline

Phase 2: 2

Top Sponsors

  • Lepu Biopharma Co., Ltd.1
  • CG Oncology, Inc.1

Indications

  • Cancer2
  • High-Risk Non-Muscle-Invasive Bladder Cancer1
  • High-grade Ta/ T1 Papillary Disease Bladder Cancer1
  • Non-Muscle Invasive Bladder Cancer1

Other1 trial

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Phase 2

Phoenix, Arizona1 trial

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Mayo Clinic Arizona

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.